Balaxi Pharmaceuticals Q2 Results FY27: PAT Jumps 447.62% to Rs 1.15 Cr, Revenue Rs 81.37 Cr

Balaxi Pharmaceuticals Ltd (BALAXI) Q2 Results FY27 announced on 12 November 2026, covering the company's financial performance for the July to September quarter. The results date brought Consolidated revenue of Rs 81.37 Cr, Operating Profit of Rs 5.12 Cr and PAT of Rs 1.15 Cr. These consolidated results show revenue up 44.84% YoY and net profit up 447.62%. This page tracks Balaxi Pharmaceuticals Q2 Results FY27 line by line.

This results analysis of Balaxi Pharmaceuticals Q2 Results covers the financial highlights, the business factors behind the quarter, the outlook and the risks. Univest has laid the numbers out so the revenue, Operating Profit and PAT movement is clear at a glance, starting with the Financial Highlights table below.

Click Here – Get Free Investment Predictions

Balaxi Pharmaceuticals Q2 Results FY27: Financial Highlights

Metric	Q2 FY27 (Sep 26)	Q2 FY26 (Sep 25)	YoY Change
Revenue	Rs 81.37 Cr	Rs 56.18 Cr	+44.84% YoY
Operating Profit	Rs 5.12 Cr	Rs 1.17 Cr	+337.61% YoY
Net Profit (PAT)	Rs 1.15 Cr	Rs 0.21 Cr	+447.62% YoY

Source: company filing for Balaxi Pharmaceuticals Q2 Results FY27, 12 November 2026. Figures in Rs Crore, Consolidated basis.

Key Takeaways from Balaxi Pharmaceuticals Q2 Results: What Stands Out

• Revenue rose to Rs 81.37 Cr from Rs 56.18 Cr a year earlier, reflecting YoY growth of 44.84% in the July to September quarter.
• Operating Profit climbed 337.61% YoY to Rs 5.12 Cr from Rs 1.17 Cr, growing well ahead of revenue in the same quarter.
• Net profit rose 447.62% YoY to Rs 1.15 Cr from Rs 0.21 Cr, so profit grew faster than revenue in Balaxi Pharmaceuticals Q2 Results FY27.
• Net profit margin improved to 1.4% from 0.4% in the comparison quarter, adding a margin view to the YoY comparison.
• The performance analysis that follows shows how revenue, Operating Profit and net profit moved together.

Balaxi Pharmaceuticals Q2 Results FY27: Performance Analysis

Balaxi Pharmaceuticals Q2 Results FY27 show profit growing faster than revenue. Revenue rose 44.84% YoY to Rs 81.37 Cr from Rs 56.18 Cr, Operating Profit rose 337.61% YoY to Rs 5.12 Cr from Rs 1.17 Cr, and net profit rose 447.62% YoY to Rs 1.15 Cr from Rs 0.21 Cr in the July to September quarter.

In absolute terms, revenue added Rs 25.19 Cr over the year-ago quarter, Operating Profit added Rs 3.95 Cr and net profit added Rs 0.94 Cr. The Balaxi Pharmaceuticals Q2 Results results analysis therefore shows each profit line expanding by a larger percentage than the top line. These quarterly results leave later disclosures as the place to see whether that pattern continues.

Taken together, Balaxi Pharmaceuticals Q2 Results FY27 describe a quarter in which the consolidated results moved higher on every reported line. Readers following YoY growth will see the largest gain in net profit, followed by Operating Profit and then revenue. The figures reported on the results date are the basis for every comparison that follows, which is where the results analysis turns to the business factors.

Check the Univest Screener for live results data

Key Business Factors This Quarter

Revenue Growth – The results analysis points first to revenue growth. Revenue grew 44.8% year on year to Rs 81.37 Cr in the latest quarter, an increase of Rs 25.19 Cr over the Rs 56.18 Cr reported a year earlier, and this sets the top line for Balaxi Pharmaceuticals Q2 Results FY27.

Net Profit Growth – Net profit rose 447.6% year on year to Rs 1.15 Cr from Rs 0.21 Cr, while Operating Profit rose to Rs 5.12 Cr from Rs 1.17 Cr. Together these two lines show how profit moved in these quarterly results.

Net Profit Margin – Net profit margin improved to 1.4% from 0.4% in the comparison quarter. This margin and the 447.62% rise in net profit form the base that the FY27 outlook builds on.

FY27 Outlook After Balaxi Pharmaceuticals Q2 Results

The FY27 outlook starts from that base of Rs 1.15 Cr in net profit. Full-year FY27 results will depend on the quarters still to be reported, so this results analysis treats the Balaxi Pharmaceuticals Q2 Results FY27 figures as one reference point rather than a full-year view.

Revenue of Rs 81.37 Cr, Operating Profit of Rs 5.12 Cr and net profit of Rs 1.15 Cr are the three numbers to compare on the next results date, and investors can follow the same figures for BALAXI on the Univest app. How these lines hold up in later disclosures leads into the risks that matter most after this quarter.

Key Risks to Watch After Balaxi Pharmaceuticals Q2 Results FY27

Low Return on Equity

Return on equity was low at 0.59% in FY26. This annual figure sits beside the stronger quarterly numbers in Balaxi Pharmaceuticals Q2 Results FY27, so the next YoY growth comparison will show whether the quarter's gains carry into annual returns.

Modest Return on Capital Employed

Return on capital employed was modest at 3.48% in FY26. This ratio describes the profit generated on the capital the business uses, and it stayed in low single digits for the full year.

Volatile Quarterly Net Profit

Quarterly net profit has been volatile, ranging from Rs 0.21 Cr to Rs 1.30 Cr over the last 5 quarters. The latest figure of Rs 1.15 Cr sits inside that range, so the pattern of later quarters matters.

Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.

Conclusion

In summary, Balaxi Pharmaceuticals Q2 Results FY27 show Consolidated revenue of Rs 81.37 Cr, up 44.84% YoY, and net profit of Rs 1.15 Cr, up 447.62%. These quarterly results and the consolidated results basis leave investors watching how profit holds in later disclosures, which is the focus of Balaxi Pharmaceuticals Q2 Results. Investors should consult a SEBI-registered advisor before acting.

Frequently Asked Questions on Balaxi Pharmaceuticals Q2 Results FY27

What are Balaxi Pharmaceuticals Q2 Results FY27?

Ans. Balaxi Pharmaceuticals Q2 Results FY27 are the July to September 2026 quarterly results declared on 12 November 2026. They show revenue of Rs 81.37 Cr and net profit of Rs 1.15 Cr, as the Financial Highlights table shows.

What is the results date for Balaxi Pharmaceuticals Q2 Results FY27?

Ans. Balaxi Pharmaceuticals declared its Q2 FY27 results on 12 November 2026, so the results date covers the July to September 2026 quarter. This is the same date given in the opening paragraphs of the article.

What revenue was reported in Balaxi Pharmaceuticals Q2 Results FY27?

Ans. Balaxi Pharmaceuticals reported Q2 FY27 revenue of Rs 81.37 Cr against Rs 56.18 Cr a year earlier, while the Financial Highlights table sets both figures side by side.

What net profit was reported in Balaxi Pharmaceuticals Q2 Results FY27?

Ans. Balaxi Pharmaceuticals Q2 Results FY27 show net profit of Rs 1.15 Cr compared with Rs 0.21 Cr in the same quarter last year, which means net profit is higher by Rs 0.94 Cr, as the Performance Analysis explains.

How much YoY growth did revenue show in Balaxi Pharmaceuticals Q2 Results FY27?

Ans. Revenue showed YoY growth of 44.84% in Q2 FY27, rising from Rs 56.18 Cr to Rs 81.37 Cr, so the top line grew by Rs 25.19 Cr, as covered under Key Business Factors.

Did net profit rise or fall in Balaxi Pharmaceuticals Q2 Results?

Ans. Net profit rose 447.62% YoY in the Balaxi Pharmaceuticals Q2 FY27 results, from Rs 0.21 Cr to Rs 1.15 Cr, while revenue also moved up, as the Key Takeaways section shows.

What was the Operating Profit in Balaxi Pharmaceuticals Q2 Results FY27?

Ans. Operating Profit was Rs 5.12 Cr in Q2 FY27 against Rs 1.17 Cr a year earlier, a rise of 337.61% YoY, as the Performance Analysis section shows.

Are Balaxi Pharmaceuticals Q2 Results consolidated results or standalone results?

Ans. Balaxi Pharmaceuticals Q2 Results are consolidated results, so the revenue of Rs 81.37 Cr and net profit of Rs 1.15 Cr are reported on a Consolidated basis, as stated in the Quick Answer.

What business factors shaped Balaxi Pharmaceuticals Q2 Results FY27?

Ans. Revenue growth of 44.8% to Rs 81.37 Cr and net profit growth of 447.6% to Rs 1.15 Cr frame Balaxi Pharmaceuticals Q2 Results FY27, so these factors lead the Key Business Factors section.

What are the key risks after Balaxi Pharmaceuticals Q2 Results FY27?

Ans. The key risks after Balaxi Pharmaceuticals Q2 Results FY27 are return on equity of 0.59%, return on capital employed of 3.48% and volatile quarterly net profit, all covered in the Key Risks section.

What is the outlook after Balaxi Pharmaceuticals Q2 Results?

Ans. The outlook after Balaxi Pharmaceuticals Q2 Results depends on later quarters, so FY27 full-year results will rest on upcoming disclosures, which is the point made in the FY27 Outlook section.

Where can I find the complete Balaxi Pharmaceuticals Q2 Results FY27 data?

Ans. The complete Balaxi Pharmaceuticals Q2 Results FY27 figures sit in the Financial Highlights table, while the Univest Screener lets investors track BALAXI numbers further, as noted in the Outlook section.